Browsing 4 Medizinische Fakultät by Author "Kampa-Schittenhelm, Kerstin Maria"

Now showing items 1-18 of 18

A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer

Kearney, Matthew R.; Chen, Emerson Y.; Vaccaro, Gina M.; Strother, John; Burt, Andrea; Todd, Kendra; Donovan, Jeff; Kampa-Schittenhelm, Kerstin M.; Lopez, Charles D. (2019)
Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS)

Tsintari, Vasileia; Walter, Bianca; Fend, Falko; Overkamp, Mathis; Rothermundt, Christian; Lopez, Charles D.; Schittenhelm, Marcus M.; Kampa-Schittenhelm, Kerstin M. (2022)
Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia

Schittenhelm, Marcus Matthias; Walter, Bianca; Tsintari, Vasileia; Federmann, Birgit; Saipi, Mihada Bajrami; Akmut, Figen; Illing, Barbara; Mau-Holzmann, Ulrike; Fend, Falko; Lopez, Charles Darin; Kampa-Schittenhelm, Kerstin Maria (2019)
Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage–response thresholds

Kampa-Schittenhelm, Kerstin Maria; Acoba, Jared D.; Chen, Dexi; Gay, Joel; Lee, Hunjoo; Beemer, Kelly; Padiernos, Emerson; Boonmark, Nataya; Zhu, Zhiyi; Fan, Alice C.; Bailey, Alex S.; Fleming, Wiliam H.; Corless, Christopher; Felsher, Dean W.; Naumovski, Louie; Lopez, Charles D. (2009)
Apoptosis-Stimulating-Proteins of p53 (ASPP) - key regulator of early oncogenesis and therapy resistance

Kampa-Schittenhelm, Kerstin Maria (2019)
ASPP2 kappa Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis

Rieger, Ingmar; Tsintari, Vasileia; Overkamp, Mathis; Fend, Falko; Lopez, Charles D.; Schittenhelm, Marcus M.; Kampa-Schittenhelm, Kerstin M. (2021)
Attenuated Expression of Apoptosis Stimulating Protein of p53-2 (ASPP2) in Human Acute Leukemia Is Associated with Therapy Failure

Schittenhelm, Marcus M.; Illing, Barbara; Ahmut, Figen; Rasp, Katharina Henriette; Blumenstock, Gunnar; Doehner, Konstanze; Lopez, Charles D.; Kampa-Schittenhelm, Kerstin M. (2013)
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia

Kampa-Schittenhelm, Kerstin Maria; Heinrich, Michael Charles; Akmut, Figen; Rasp, Katharina Henriette; Illing, Barbara; Doehner, Hartmut; Doehner, Konstanze; Schittenhelm, Marcus Matthias (2013)
Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia

Kampa-Schittenhelm, Kerstin Maria; Frey, Julia; Haeusser, Lara A.; Illing, Barbara; Pavlovsky, Ashly A.; Blumenstock, Gunnar; Schittenhelm, Marcus Matthias (2017)
Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns

Kampa-Schittenhelm, Kerstin Maria; Salitzky, Olaf; Akmut, Figen; Illing, Barbara; Kanz, Lothar; Salih, Helmut Rainer; Schittenhelm, Marcus Matthias (2016)
Epigenetic activation of O-linked beta-N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia

Kampa-Schittenhelm, K. M.; Haverkamp, T.; Bonin, M.; Tsintari, V; Buehring, H. J.; Haeusser, L.; Blumenstock, G.; Dreher, S. T.; Ganief, T.; Akmut, F.; Illing, B.; Mau-Holzmann, U. A.; Bonzheim, I; Schleicher, E.; Vogel, W.; Schittenhelm, M. M. (2020)
Evaluation of apoptosis stimulating protein of TP53-1 (ASPP1/PPP1R13B) to predict therapy resistance and overall survival in acute myeloid leukemia (AML)

Schittenhelm, Marcus M.; Kaiser, Max; Gyorffy, Balazs; Kampa-Schittenhelm, Kerstin M. (2024)
High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML)

Saipi, Mihada Bajrami; Ruiba, Alessia; Schittenhelm, Marcus Matthias; Blumenstock, Gunnar; Gyorffy, Balazs; Fazio, Serena; Hafner, Marlon; Ahrens, Anna-Lena; Aldinger, Lara; Aellig, Vanessa; Kavelaars, Francois G.; Nombela-Arrieta, Cesar; Fend, Falko; Valk, Peter J. M.; Christoph, Driessen; Kampa-Schittenhelm, Kerstin Maria (2024)
N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence

Wang, Zhiping; Liu, Yuangang; Takahashi, Maho; Van Hook, Kathryn; Kampa-Schittenhelm, Kerstin M.; Sheppard, Brett C.; Sears, Rosalie C.; Stork, Philip J. S.; Lopez, Charles D. (2013)
New insights into the expanding complexity of the tumor suppressor ASPP2

Kampa-Schittenhelm, Kerstin Maria; Bonin, Michael; Lopez, Charles D. (2009)
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms

Kampa-Schittenhelm, Kerstin Maria; Heinrich, Michael Charles; Akmut, Figen; Doehner, Hartmut; Doehner, Konstanze; Schittenhelm, Marcus Matthias (2013)
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin

Schittenhelm, Marcus M.; Kampa-Schittenhelm, Kerstin Maria; Yee, Kevin W. H.; Heinrich, Michael C. (2009)
The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro

Krusch, Matthias; Salih, Julia; Schlicke, Manuela; Baessler, Tina; Kampa-Schittenhelm, Kerstin-Maria; Mayer, Frank; Salih, Helmut Rainer (2009)

Now showing items 1-18 of 18

Report a Publication

Help

Browse

All of DSpace
This Collection

Browsing 4 Medizinische Fakultät by Author "Kampa-Schittenhelm, Kerstin Maria"

DSpace Repository

Browsing 4 Medizinische Fakultät by Author "Kampa-Schittenhelm, Kerstin Maria"

Browse

All of DSpace

This Collection

My Account